Using CDDP and other medications, successfully silenced the PON2 gene in several kinds of cancer cell lines, resulting in notable drops in PON2 mRNA and protein levels (Campagna et al. 2020, 2022, 2023; Belloni et al. 2025). Here, PON2 is linked to cancer.